Danaher Reports Record Third Quarter 2015 Results

WASHINGTON, Oct. 22, 2015 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced record results for the third quarter 2015.

For the quarter ended October 2, 2015, non-GAAP adjusted diluted net earnings per share from continuing operations were $1.05, which reflects the adjustments identified in the attached reconciliation schedule. On a GAAP basis, diluted net earnings from continuing operations for the third quarter were $590 million, or $0.85 per diluted share. Revenue for the third quarter 2015 increased 6.5% to $5.0 billion with core revenues increasing 3.0%.

The Company anticipates that non-GAAP, adjusted diluted net earnings per share from continuing operations for the fourth quarter 2015 will be in the range of $1.25 to $1.29.

Thomas P. Joyce, Jr., President and Chief Executive Officer, stated, "Danaher had another good quarter with solid core revenue growth, free cash flow and earnings performance. In a challenging global macro environment, we've continued to enhance our businesses through organic growth initiatives and strategic acquisitions, most notably Pall. As we move forward, we believe the strength of our portfolio, combined with our team's steadfast execution through the Danaher Business System, will help us continue to deliver strong operating results and shareholder value."

Danaher will discuss its results during its quarterly investor conference call today starting at 8:00 a.m. ET. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Investor Events." A replay of the webcast will be available in the same section of Danaher's website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.

The conference call can be accessed by dialing 888-215-6894 within the U.S. or by dialing 913-312-1434 outside the U.S. a few minutes before the 8:00 a.m. ET start and telling the operator that you are dialing in for Danaher's investor conference call (access code 357158). A replay of the conference call will be available shortly after the conclusion of the call and until Thursday, October 29, 2015. The replay can be accessed by dialing 888-203-1112 within the U.S. or 719-457-0820 outside the U.S. with the access code 357158. In addition, presentation materials relating to Danaher's results have been posted to the "Investors" section of Danaher's website under the subheading "Events & Presentations."

ABOUT DANAHER

Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Our family of world-class brands has leadership positions in some of the most demanding and attractive industries, including health care, environmental and industrial. The Company's globally diverse team of approximately 80,000 associates is united by a common culture and operating system, the Danaher Business System. In 2014, Danaher generated $19.9 billion in revenue and its market capitalization exceeded $60 billion. For more information please visit: www.danaher.com.

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings release also contains non-GAAP financial measures. The reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures and other information relating to these measures are included in the supplemental reconciliation schedule attached.

FORWARD LOOKING STATEMENTS

Statements in this release that are not strictly historical, including the statements regarding the Company's anticipated adjusted diluted net earnings per share from continuing operations for the fourth quarter 2015, the anticipated impact from the Company's growth investments and strategic acquisitions, the Company's operating results and shareholder value, and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, deterioration of or instability in the economy, the markets we serve and the financial markets, the impact of our restructuring activities on our ability to grow, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our ability to successfully identify, consummate and integrate appropriate acquisitions and successfully complete divestitures and other dispositions, contingent liabilities relating to acquisitions and divestitures, our ability to integrate the recent acquisition of Pall Corporation and achieve the anticipated benefits of that transaction, our ability to successfully consummate the separation of Danaher into two public companies and realize the anticipated benefits of that transaction, our compliance with applicable laws and regulations (including regulations relating to medical devices and the healthcare industry) and changes in applicable laws and regulations, our ability to effectively address cost reductions and other changes in the healthcare industry, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, risks relating to product, service or software defects, product liability and recalls, risks relating to product manufacturing, the impact of our debt obligations on our operations and liquidity, our relationships with and the performance of our channel partners, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole sources of supply, labor matters, international economic, political, legal, compliance and business factors, disruptions relating to man-made and natural disasters, security breaches or other disruptions of our information technology systems and pension plan costs. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2014 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2015. These forward-looking statements speak only as of the date of this release and the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

 

DANAHER CORPORATION

CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS

($ and shares in millions, except per share amounts)

(unaudited)



Three Months Ended


Nine Months Ended


October 2, 2015


September 26, 2014


October 2, 2015


September 26, 2014

Sales

$

5,023.4



$

4,707.1



$

14,678.3



$

13,929.8

Cost of sales

(2,386.4)



(2,254.8)



(6,929.1)



(6,699.6)

Gross profit

2,637.0



2,452.3



7,749.2



7,230.2

Operating costs:








Selling, general and administrative expenses

(1,528.3)



(1,298.0)



(4,346.9)



(3,894.1)

Research and development expenses

(307.9)



(288.1)



(912.0)



(856.3)

Operating profit

800.8



866.2



2,490.3



2,479.8

Non-operating income (expense):








Other income

12.4



38.2



12.4



57.4

Interest expense

(45.3)



(29.6)



(103.7)



(93.4)

Interest income

0.6



3.6



5.3



12.2

Earnings from continuing operations before income taxes

768.5



878.4



2,404.3



2,456.0

Income taxes

(178.5)



(197.1)



(540.8)



(562.4)

Net earnings from continuing operations

590.0



681.3



1,863.5



1,893.6

Earnings (loss) from discontinued operations, net of income taxes

813.3



(0.7)



805.3



43.1

Net earnings

$

1,403.3



$

680.6



$

2,668.8



$

1,936.7

Net earnings per share from continuing operations:








Basic

$

0.86



$

0.97



$

2.66



$

2.70

Diluted

$

0.85



$

0.95



$

2.62



$

2.65

Net earnings per share from discontinued operations:








Basic

$

1.18



$



$

1.15



$

0.06

Diluted

$

1.16



$



$

1.13



$

0.06

Net earnings per share:








Basic

$

2.04



$

0.97



$

3.80


*

$

2.76

Diluted

$

2.01



$

0.95



$

3.75



$

2.71

Average common stock and common equivalent shares outstanding:








Basic

688.5



702.6



701.7



701.3

Diluted

698.7



716.2



712.3



715.6









* Earnings per share amount does not add due to rounding.

 

This information is presented for reference only.  A complete copy of Danaher's Form 10-Q financial statements is available on the Company's website (www.danaher.com).


 

DANAHER CORPORATION

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES


Diluted Net Earnings Per Share From Continuing Operations



Three Months Ended


Nine Months Ended


October 2,
2015


September 26,
2014


October 2,
2015


September 26,
2014

Diluted Net Earnings Per Share From Continuing Operations
(GAAP)

$

0.85



$

0.95



$

2.62



$

2.65


Fair value adjustments to Nobel Biocare acquisition-related inventory ($20 million pre-tax, $15 million after-tax) incurred in the three months ended April 3, 2015





0.02




Acquisition-related transaction costs deemed significant ($21 million pre-tax, $16 million after-tax), change in control payments, and fair value adjustments to inventory balances ($47 million pre-tax, $36 million after-tax), in each case related to the acquisition of Pall Corporation and incurred in the three months ended October 2, 2015

0.07





0.07




Gain on sale of marketable securities in the three months ended October 2, 2015 ($12 million pre-tax, $8 million after-tax) and in the three months ended June 27, 2014 ($19 million pre-tax, $12 million after-tax)

(0.01)





(0.01)



(0.02)


Costs incurred in the three months ended October 2, 2015 ($9 million pre-tax, $7 million after-tax) related to preparation for Danaher's 2016 separation

0.01





0.01




Gain on sale of a product line ($34 million pre-tax, $26 million after-tax) in the three months ended September 26, 2014



(0.04)





(0.04)


Discrete income tax items incurred in the three months ended July 3, 2015 ($16 million) and the three months ended September 26, 2014 ($8 million)



(0.01)



(0.02)



(0.01)


Amortization of acquisition-related intangible assets in the three months ($120 million pre-tax, $92 million after-tax) and nine months ($320 million pre-tax, $246 million after-tax) ended October 2, 2015 and in the three months ($90 million pre-tax, $69 million after-tax) and nine months ($260 million pre-tax, $199 million after-tax) ended September 26, 2014

0.13



0.09



0.34



0.27


Adjusted Diluted Net Earnings Per Share From Continuing Operations (Non-GAAP)

$

1.05



$

0.99



$

3.03



$

2.85


 

Forecasted Diluted Earnings Per Share From Continuing Operations








Three Months Ending
December 31, 2015


Three Months
Ended

December 31, 2014


Low End


High End


Diluted Net Earnings Per Share From Continuing Operations
(GAAP)

$

0.99



$

1.03



$

0.90


Acquisition-related fair value adjustments to inventory and deferred revenue balances ($65 million pre-tax, $50 million after-tax), in each case related to the acquisition of Pall Corporation and to be incurred in the three months ending December 31, 2015

0.07



0.07




Costs to be incurred in the three months ending December 31, 2015 ($13 million pre-tax, $10 million after-tax) related to preparation for Danaher's 2016 separation

0.01



0.01




Impact of discrete income tax items in 2014 and lower than expected effective tax rate (due primarily to year-end 2014 tax law changes) in the three months ended December 31, 2014





0.09


Gain on sale of marketable equity securities in the three months ended December 31, 2014 ($99 million pre-tax, $62 million after-tax)





(0.09)


Restructuring charges in excess of amounts originally budgeted and publicly communicated in December 2013 for the three months ended December 31, 2014 ($91 million pre-tax and $70 million after-tax)





0.10


Acquisition-related transaction costs deemed significant ($12 million pre-tax, $9 million after-tax) and fair value adjustments to acquisition related inventory ($5 million pre-tax, $4 million after-tax) for the three months ended December 31, 2014 in each case incurred in connection with the acquisition of Nobel Biocare





0.02


Amortization of acquisition-related intangible assets in the three months ($162 million pre-tax, $124 million after-tax) ending December 31, 2015 and in the three months ($92 million pre-tax, $70 million after-tax) ended December 31, 2014

0.18



0.18



0.10


Adjusted Diluted Net Earnings Per Share from Continuing Operations (Non-GAAP)

$

1.25



$

1.29



$

1.12














Year-over-year change


12

%



15

%





 

Core Revenue Growth








Components of Revenue Growth

Three Months Ended
October 2, 2015 vs.
Comparable 2014
Period


Nine Months Ended
October 2, 2015 vs.
Comparable 2014
Period

Core (Non-GAAP)

3.0

%


4.0

%

Acquisitions (Non-GAAP)

10.5

%


8.0

%

Impact of Currency Translation (Non-GAAP)

(7.0)

%


(6.5)

%

Total Revenue Growth (GAAP)

6.5

%


5.5

%

 

Adjusted Diluted Net Earnings Per Share From Continuing Operations

We disclose the non-GAAP measure of adjusted diluted net earnings per share from continuing operations, which refers to GAAP diluted net earnings per share from continuing operations, excluding the items identified in the reconciliation schedule above.  This non-GAAP measure should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies.

Management believes that this measure provides useful information to investors by reflecting additional ways of viewing aspects of Danaher's operations that, when reconciled to the corresponding GAAP measure, helps our investors to better understand the long-term profitability trends of our business, and facilitates easier comparisons of our profitability to prior and future periods and to our peers.  The items described above have been excluded from this measure because items of this nature and/or size occur with inconsistent frequency, occur for reasons that may be unrelated to Danaher's commercial performance during the period and/or we believe are not indicative of Danaher's ongoing operating costs or gains in a given period, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult.  The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company's larger acquisitions) if it determines that such costs exceed the range of acquisition-related transaction costs typical for Danaher in a given period.

The Company estimates the tax effect of the items identified in the reconciliation schedule above by applying the Company's overall estimated effective tax rate to the pre-tax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment.

Core Revenue and Core Revenue Growth

We use the term "core revenue" or "sales from existing businesses" to refer to GAAP revenue from existing operations excluding (1) sales from acquired businesses recorded prior to the first anniversary of the acquisition less the amount of sales attributable to divested product lines not considered discontinued operations ("acquisition sales"), and (2) the impact of currency translation.  The portion of GAAP revenue from existing operations attributable to currency translation is calculated as the difference between (a) the period-to-period change in revenue (excluding acquisition sales) and (b) the period-to-period change in revenue (excluding acquisition sales) after applying current period foreign exchange rates to the prior year period.  We use the term "core revenue growth" to refer to the measure of comparing current period core revenue with the corresponding period of the prior year.  These non-GAAP measures should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measures, and may not be comparable to similarly titled measures reported by other companies.

Management believes that these non-GAAP measures provide useful information to investors by helping identify underlying growth trends in our business and facilitating easier comparisons of our revenue performance with prior and future periods and to our peers.  We exclude the effect of currency translation from these measures because currency translation is not under management's control, is subject to volatility and can obscure underlying business trends.  We exclude the effect of acquisitions and divested product lines because the nature, size and number of such transactions can vary dramatically from period to period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult.

SOURCE Danaher Corporation

For further information: Matthew E. Gugino, Vice President, Investor Relations, Danaher Corporation, 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, D.C. 20037, Telephone: (202) 828-0850, Fax: (202) 828-0860

rss